S&P 500
5.071,63 +1,08 (+0,02%) Nasdaq
15.712,75 +16,11 (+0,10%) NIKKEI 225
37.675,74 -784,34 (-2,04%) Dólar/Euro
1,0711 +0,0010 (+0,10%) Petróleo Brent
88,16 +0,14 (+0,16%) Bitcoin EUR
59.892,83 -2.519,77 (-4,04%)
Clearside Biomedical, Inc. (CLSD)
Después del cierre:
Clearside Biomedical, Inc.
900 North Point Parkway
Suite 200
Alpharetta, GA 30005
United States
678 270 3631
https://clearsidebio.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 30
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | President, CEO & Director | 816,4k | N/A | 1952 |
| Mr. Charles A. Deignan | Chief Financial Officer | 536,95k | N/A | 1964 |
| Dr. Thomas A. Ciulla M.B.A., M.D. | Chairman of Scientific Advisory Board | 597,21k | N/A | 1965 |
| Ms. Jenny R. Kobin | Head of Investor Relations | N/A | N/A | 1967 |
| Mr. Rafael V. Andino | Senior Vice President of Engineering & Manufacturing | N/A | N/A | 1965 |
| Ms. Susan L. Coultas Ph.D. | Chief Clinical Officer | N/A | N/A | N/A |
| Dr. Ngai Hang Chong M.B.A., M.D. | Chief Medical Officer | N/A | N/A | N/A |
| Mr. Leslie B. Zacks | Secretary | N/A | N/A | 1969 |
Descripción
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Gobierno corporativo
El ISS Governance QualityScore de Clearside Biomedical, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
